Source: streetinsider

Press Release: Entasis : Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections

WALTHAM, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today announced the initiation of the ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 pivotal clinical trial to evaluate ETX2514SUL, a fixed-dose combination of its broad-spectrum β-lactamase inhibitor ETX2514 with sulbactam, for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Manos Perros's photo - President & CEO of Entasis Therapeutics Holdings, Inc.

President & CEO

Manos Perros

CEO Approval Rating


Entasis is a biotechnology company that develops and commercializes antibiotic therapies for the treatment of bacterial infections. Read more